Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunity & Ageing
Published in: Immunity & Ageing 1/2016

Open Access 01-12-2016 | Research

Cellular immune activity biomarker neopterin is associated hyperlipidemia: results from a large population-based study

Authors: Shu-Chun Chuang, Heiner Boeing, Stein Emil Vollset, Øivind Midttun, Per Magne Ueland, Bas Bueno-de-Mesquita, Martin Lajous, Guy Fagherazzi, Marie-Christine Boutron-Ruault, Rudolf Kaaks, Tilman Küehn, Tobias Pischon, Dagmar Drogan, Anne Tjønneland, Kim Overvad, J Ramón Quirós, Antonio Agudo, Esther Molina-Montes, Miren Dorronsoro, José María Huerta, Aurelio Barricarte, Kay-Tee Khaw, Nicholas J. Wareham, Ruth C. Travis, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Giovanna Masala, Claudia Agnoli, Rosario Tumino, Amalia Mattiello, Petra H Peeters, Elisabete Weiderpass, Richard Palmqvist, Ingrid Ljuslinder, Marc Gunter, Yunxia Lu, Amanda J. Cross, Elio Riboli, Paolo Vineis, Krasimira Aleksandrova

Published in: Immunity & Ageing | Issue 1/2016

Login to get access

Abstract

Background

Increased serum neopterin had been described in older age two decades ago. Neopterin is a biomarker of systemic adaptive immune activation that could be potentially implicated in metabolic syndrome (MetS). Measurements of waist circumference, triglycerides, high-density lipoprotein cholesterol (HDLC), systolic and diastolic blood pressure, glycated hemoglobin as components of MetS definition, and plasma total neopterin concentrations were performed in 594 participants recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Results

Higher total neopterin concentrations were associated with reduced HDLC (9.7 %, p < 0.01 for men and 9.2 %, p < 0.01 for women), whereas no association was observed with the rest of the MetS components as well as with MetS overall (per 10 nmol/L: OR = 1.42, 95 % CI = 0.85-2.39 for men and OR = 1.38, 95 % CI = 0.79-2.43).

Conclusions

These data suggest that high total neopterin concentrations are cross-sectionally associated with reduced HDLC, but not with overall MetS.
Literature
1.
Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Lett. 2010;287:13–22.CrossRefPubMed
2.
Oxenkrug G, Tucker KL, Requintina P, Summergrad P. Neopterin, a marker of interferon-gamma-inducible inflammation, correlates with pyridoxal-5'-phosphate, waist circumference, hdl-cholesterol, insulin resistance and mortality risk in adult boston community dwellers of Puerto Rican origin. Am J Neuroprot Neuroregen. 2011;3:48–52.PubMedCentralCrossRefPubMed
3.
Oxenkrug GF. Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders. J Neural Transm. 2011;118:75–85.PubMedCentralCrossRefPubMed
4.
Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2009;55:1135–46.CrossRefPubMed
5.
Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002;3:175–87.CrossRefPubMed
6.
Weiss G, Widner B, Zoller H, Schobersberger W, Fuchs D. Immune response and iron metabolism. Br J Anaesth. 1998;81 Suppl 1:6–9.PubMed
7.
Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res. 2003;52:313–21.CrossRefPubMed
8.
Oxenkrug G. Interferon-gamma - inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis. 2011;2:474–86.PubMedCentralPubMed
9.
Capuron L, Geisler S, Kurz K, Leblhuber F, Sperner-Unterweger B, Fuchs D. Activated immune system and inflammation in healthy ageing: relevance for tryptophan and neopterin metabolism. Curr Pharm Des. 2014;20:6048–57.CrossRefPubMed
10.
Ledochowski M, Murr C, Widner B, Fuchs D. Association between insulin resistance, body mass and neopterin concentrations. Clin Chim Acta. 1999;282:115–23.CrossRefPubMed
11.
Spencer ME, Jain A, Matteini A, Beamer BA, Wang NY, Leng SX, et al. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci. 2010;65:858–65.CrossRefPubMed
12.
Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1–14.CrossRefPubMed
13.
Avanzas P, Arroyo-Espliguero R, Kaski JC. Neopterin and cardiovascular disease: growing evidence for a role in patient risk stratification. Clin Chem. 2009;55:1056–7.CrossRefPubMed
14.
15.
16.
Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18:363–74.CrossRefPubMed
17.
Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007;115:3071–8.CrossRefPubMed
18.
Thewissen MM, Damoiseaux JG, Duijvestijn AM, van Greevenbroek MM, van der Kallen CJ, Feskens EJ, et al. Abdominal fat mass is associated with adaptive immune activation: the CODAM Study. Obesity (Silver Spring). 2011;19:1690–8.CrossRef
19.
Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ, Cruz-Fernandez JM, Garcia-Moll X, Marrugat J, et al. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis. 2008;201:176–83.CrossRefPubMed
20.
Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:1149–56.PubMed
21.
22.
Norata GD, Pirillo A, Ammirati E, Catapano AL. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2012;220:11–21.CrossRefPubMed
23.
Holven KB, Retterstol K, Ueland T, Ulven SM, Nenseter MS, Sandvik M, et al. Subjects with low plasma HDL cholesterol levels are characterized by an inflammatory and oxidative phenotype. PLoS One. 2013;8, e78241.PubMedCentralCrossRefPubMed
24.
Garcia-Moll X, Cole D, Zouridakis E, Kaski JC. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart. 2000;83:346–50.PubMedCentralCrossRefPubMed
25.
Sulo G, Vollset SE, Nygard O, Midttun O, Ueland PM, Eussen SJ, et al. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int J Cardiol. 2013;168(2):1435–40.CrossRefPubMed
26.
Ursavas A, Karadag M, Oral AY, Demirdogen E, Oral HB, Ege E. Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea. Respir Med. 2008;102:1193–7.CrossRefPubMed
27.
Theofylaktopoulou D, Midttun O, Ulvik A, Ueland PM, Tell GS, Vollset SE, et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013;173:121–30.PubMedCentralCrossRefPubMed
28.
van Haelst PL, Liem A, van Boven AJ, Veeger NJ, van Veldhuisen DJ, Tervaert JW, et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol. 2003;92:1201–3.CrossRefPubMed
29.
Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol. 2004;93:627–9.CrossRefPubMed
30.
Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J. 2005;26:457–63.CrossRefPubMed
31.
Pacileo M, Cirillo P, De RS, Ucci G, Petrillo G, Musto DS, et al. The role of neopterin in cardiovascular disease. Monaldi Arch Chest Dis. 2007;68:68–73.PubMed
32.
Schennach H, Murr C, Gachter E, Mayersbach P, Schonitzer D, Fuchs D. Factors influencing serum neopterin concentrations in a population of blood donors. Clin Chem. 2002;48:643–5.PubMed
33.
de Metz J, Sprangers F, Endert E, Ackermans MT, ten Berge IJ, Sauerwein HP, et al. Interferon-gamma has immunomodulatory effects with minor endocrine and metabolic effects in humans. J Appl Physiol. 1999;86:517–22.PubMed
34.
Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113–24.CrossRefPubMed
35.
Aleksandrova K, Boeing H, Jenab M, Bas Bueno-de-Mesquita H, Jansen E, van Duijnhoven FJ, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila). 2011;4:1873–83.CrossRef
36.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMed
37.
Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23:1371–9.CrossRefPubMed
38.
van Duijnhoven FJ, Bueno-de-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European prospective investigation into cancer and nutrition. Gut. 2011;60:1094–102.CrossRefPubMed
39.
Rinaldi S, Rohrmann S, Jenab M, Biessy C, Sieri S, Palli D, et al. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008;17:3108–15.CrossRefPubMed
40.
Eussen SJ, Vollset SE, Igland J, Meyer K, Fredriksen A, Ueland PM, et al. Plasma folate, related genetic variants, and colorectal cancer risk in EPIC. Cancer Epidemiol Biomarkers Prev. 2010;19:1328–40.PubMedCentralCrossRefPubMed
41.
Eussen SJ, Vollset SE, Hustad S, Midttun O, Meyer K, Fredriksen A, et al. Plasma vitamins B2, B6, and B12, and related genetic variants as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2010;19:2549–61.PubMedCentralCrossRefPubMed
Metadata
Title
Cellular immune activity biomarker neopterin is associated hyperlipidemia: results from a large population-based study
Authors
Shu-Chun Chuang
Heiner Boeing
Stein Emil Vollset
Øivind Midttun
Per Magne Ueland
Bas Bueno-de-Mesquita
Martin Lajous
Guy Fagherazzi
Marie-Christine Boutron-Ruault
Rudolf Kaaks
Tilman Küehn
Tobias Pischon
Dagmar Drogan
Anne Tjønneland
Kim Overvad
J Ramón Quirós
Antonio Agudo
Esther Molina-Montes
Miren Dorronsoro
José María Huerta
Aurelio Barricarte
Kay-Tee Khaw
Nicholas J. Wareham
Ruth C. Travis
Antonia Trichopoulou
Pagona Lagiou
Dimitrios Trichopoulos
Giovanna Masala
Claudia Agnoli
Rosario Tumino
Amalia Mattiello
Petra H Peeters
Elisabete Weiderpass
Richard Palmqvist
Ingrid Ljuslinder
Marc Gunter
Yunxia Lu
Amanda J. Cross
Elio Riboli
Paolo Vineis
Krasimira Aleksandrova
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2016
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/s12979-016-0059-y

Other articles of this Issue 1/2016

Immunity & Ageing 1/2016 Go to the issue

Research

HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection

Research

β-glucans: ex vivo inflammatory and oxidative stress results after pasta intake

Research

TLR-6 SNP P249S is associated with healthy aging in nonsmoking Eastern European Caucasians - A cohort study

Research

Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration

Review

Dietary phytochemicals and neuro-inflammaging: from mechanistic insights to translational challenges

Research

Role of androgens in dhea-induced rack1 expression and cytokine modulation in monocytes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits